Taivex Therapeutics attended the 2024 BIO-Europe SPRING conference in Barcelona, Spain (https://informaconnect.com/bioeurope-spring/) from March 18th to 20th. During the conference, Taivex engaged in discussions with
T-1301 Phase I clinical trial was initiated in Mid-December, 2021 in multiple centers in Taiwan. Getting through the tough 2022Q2 due to COVID-19 affected patient
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment
Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer
Taivex corporate with Development Center for Biotechnology (DCB), developed a first-in-class small molecule drug, T-1101. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block
